Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia

Although inotuzumab ozogamicin (InO) is recognized as an effective agent in relapsed acute lymphoblastic leukemia (ALL) in adults, data on safety and efficacy in pediatric patients are scarce. We report the use of InO in 51 children with relapsed/refractory ALL treated in the compassionate use progr...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhojwani, Deepa, Sposto, Richard, Shah, Nirali N., Rodriguez, Vilmarie, Yuan, Constance, Stetler-Stevenson, Maryalice, O’Brien, Maureen M., McNeer, Jennifer L., Quereshi, Amrana, Cabannes, Aurelie, Schlegel, Paul, Rossig, Claudia, Dalla-Pozza, Luciano, August, Keith, Alexander, Sarah, Bourquin, Jean-Pierre, Zwaan, Michel, Raetz, Elizabeth A., Loh, Mignon L., Rheingold, Susan R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6438769/
https://www.ncbi.nlm.nih.gov/pubmed/30267011
http://dx.doi.org/10.1038/s41375-018-0265-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6438769/
https://www.ncbi.nlm.nih.gov/pubmed/30267011
http://dx.doi.org/10.1038/s41375-018-0265-z

Ejemplares similares